Celyad Oncology S.A.
CYAD
Rang in Aktien
#31680
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Aktienkurs
$0.24909259
Marktkapitalisierung
$11.77M
Veränderung (1 Tag)
1.94%
Veränderung (1 Jahr)
-14.21%
Land
BE
Handel Celyad Oncology S.A. (CYAD)
Kategorie
Healthcare
P/S-Verhältnis für Celyad Oncology S.A. (CYAD)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Celyad Oncology S.A. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Celyad Oncology S.A. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
| Jahr | P/S-Verhältnis | ändert |
|---|---|---|
| Nicht genügend Daten für die angegebenen Daten. | ||
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | P/S-Verhältnis | P/S-Verhältnis-Differenz | Land |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
